Rho Kinase and Carbonic Anhydrase Inhibitor Combination for Glaucoma
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for glaucoma and ocular hypertension, including Rho kinase inhibitors and carbonic anhydrase inhibitors, have limitations in potency and duration of ocular hypotensive effect, particularly in normal tension glaucoma, necessitating a more effective combination therapy.
Innovation Solution
A combination of Rho kinase inhibitors and carbonic anhydrase inhibitors is administered to enhance ocular hypotensive effects and prolong the duration of action, using specific compounds like (S)-(-)-1-(4-fluoro-5-isoquinolinesulfonyl)-2-methyl-1,4-homopiperazine and brinzolamide, which are administered together or separately at intervals.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Device complexity
If single-drug therapy with Rho kinase inhibitors or carbonic anhydrase inhibitors is used, then the treatment is simple, but the ocular hypotensive effect is insufficient and duration is short
Solution Approach 1:
The patent combines Rho kinase inhibitors and carbonic anhydrase inhibitors into a single ophthalmic preparation, merging two different mechanisms of action (increasing aqueous outflow and decreasing aqueous production) to achieve synergistic ocular hypotensive effects while maintaining ease of administration as a single drop
2Ease of operation
If single-drug therapy is used, then the administration is simple, but the duration of ocular hypotensive action is short
Solution Approach 1:
The patent formulates both Rho kinase inhibitor and carbonic anhydrase inhibitor in a single ophthalmic preparation, allowing simultaneous delivery of two drugs with different durations of action, thereby extending the overall duration of ocular hypotensive effect while maintaining simple once-daily administration
3Reliability
If combination therapy with multiple drugs is used, then the ocular hypotensive effect is enhanced, but the treatment complexity increases
Solution Approach 1:
The patent combines multiple active ingredients (Rho kinase inhibitor and carbonic anhydrase inhibitor) into a single ophthalmic preparation, achieving the benefits of combination therapy (enhanced and prolonged ocular hypotensive effect) while eliminating the complexity of administering multiple separate medications
4Reliability
If existing drug combinations are used, then some ocular hypotensive effect is achieved, but the effect is insufficient for normal tension glaucoma
Solution Approach 1:
The patent changes the pharmacological parameters by selecting specific compounds with optimized properties: Rho kinase inhibitor (fasudil) for increasing aqueous outflow and carbonic anhydrase inhibitor (brinzolamide) for decreasing aqueous production, creating a combination that achieves sufficient hypotensive effect even in normal tension glaucoma where larger pressure reductions are needed
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The combination therapy provides a potent and prolonged ocular hypotensive effect, effectively lowering intraocular pressure even in normal tension glaucoma, with improved clinical efficacy compared to single-drug treatments.
Implementation Method 1
it is further suggested that this action may be attributed to changes in the cytoskeleton of a trabecular meshwork cells
Implementation Method 2
carbonic anhydrase inhibitors are known to lower IOP by internal use or instillation thereof because they inhibit the production of aqueous humor in the ciliary body
Data Source
Figure 1~2
AI summary
There is provided an agent for prevention of glaucoma or an agent for prevention or treatment of ocular hypertension, with a potent ocular hypotensive effect and prolonged duration thereof. An agent for prevention or treatment of glaucoma comprising a Rho kinase inhibitor and a carbonic anhydrase inhibitor in combination.